These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 27556701)

  • 1. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
    Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
    Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients.
    Meng P; Wei J; Geng Y; Chen S; Terpstra MM; Huang Q; Zhang Q; Su Z; Yu W; Su M; Kok K; van den Berg A; Gu J
    BMC Cancer; 2019 Aug; 19(1):818. PubMed ID: 31429737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma.
    Luo H; Li H; Hu Z; Wu H; Liu C; Li Y; Zhang X; Lin P; Hou Q; Ding G; Wang Y; Li S; Wei D; Qiu F; Li Y; Wu S
    Biochem Biophys Res Commun; 2016 Mar; 471(4):596-602. PubMed ID: 26876573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Cell-Free DNA Levels Could Predict Oncological Outcomes of Patients Undergoing Esophagectomy for Esophageal Squamous Cell Carcinoma.
    Hsieh CC; Hsu HS; Chang SC; Chen YJ
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999323
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Nasrollahzadeh D; Roshandel G; Delhomme TM; Avogbe PH; Foll M; Saidi F; Poustchi H; Sotoudeh M; Malekzadeh R; Brennan P; Mckay J; Hainaut P; Abedi-Ardekani B
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
    Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
    Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing.
    Sasaki Y; Tamura M; Koyama R; Nakagaki T; Adachi Y; Tokino T
    World J Gastroenterol; 2016 Feb; 22(7):2284-93. PubMed ID: 26900290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
    Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
    Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.
    Ng CKY; Di Costanzo GG; Tosti N; Paradiso V; Coto-Llerena M; Roscigno G; Perrina V; Quintavalle C; Boldanova T; Wieland S; Marino-Marsilia G; Lanzafame M; Quagliata L; Condorelli G; Matter MS; Tortora R; Heim MH; Terracciano LM; Piscuoglio S
    Ann Oncol; 2018 May; 29(5):1286-1291. PubMed ID: 29509837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma.
    Tong YS; Wang XW; Zhou XL; Liu ZH; Yang TX; Shi WH; Xie HW; Lv J; Wu QQ; Cao XF
    Mol Cancer; 2015 Jan; 14():3. PubMed ID: 25608466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Burden Monitoring with Circulating Tumor DNA During Treatment in Patients with Esophageal Squamous Cell Carcinoma.
    Morimoto Y; Matsuda S; Kawakubo H; Nakamura K; Kobayashi R; Hisaoka K; Okui J; Takeuchi M; Aimono E; Fukuda K; Nakamura R; Saya H; Nishihara H; Kitagawa Y
    Ann Surg Oncol; 2023 Jun; 30(6):3747-3756. PubMed ID: 36788188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence.
    Pasternack H; Fassunke J; Plum PS; Chon SH; Hescheler DA; Gassa A; Merkelbach-Bruse S; Bruns CJ; Perner S; Hallek M; Büttner R; Bollschweiler E; Hölscher AH; Quaas A; Zander T; Weiss J; Alakus H
    Sci Rep; 2018 Oct; 8(1):14941. PubMed ID: 30297788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.
    Azad TD; Chaudhuri AA; Fang P; Qiao Y; Esfahani MS; Chabon JJ; Hamilton EG; Yang YD; Lovejoy A; Newman AM; Kurtz DM; Jin M; Schroers-Martin J; Stehr H; Liu CL; Hui AB; Patel V; Maru D; Lin SH; Alizadeh AA; Diehn M
    Gastroenterology; 2020 Feb; 158(3):494-505.e6. PubMed ID: 31711920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma microRNA-19a as a potential biomarker for esophageal squamous cell carcinoma diagnosis and prognosis.
    Bai Y; Lin H; Fang Z; Luo Q; Fang Y; Su Y; Hu Q; Duan H; Chen F; Zhang ZY
    Biomark Med; 2017 May; 11(5):431-441. PubMed ID: 28621611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Alterations in Esophageal Tissues From Squamous Dysplasia to Carcinoma.
    Liu X; Zhang M; Ying S; Zhang C; Lin R; Zheng J; Zhang G; Tian D; Guo Y; Du C; Chen Y; Chen S; Su X; Ji J; Deng W; Li X; Qiu S; Yan R; Xu Z; Wang Y; Guo Y; Cui J; Zhuang S; Yu H; Zheng Q; Marom M; Sheng S; Zhang G; Hu S; Li R; Su M
    Gastroenterology; 2017 Jul; 153(1):166-177. PubMed ID: 28365443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of plasma miRNA-718 for esophageal squamous cell carcinoma.
    Sun L; Dong S; Dong C; Sun K; Meng W; Lv P; Yin H; Ming L; He F
    Cancer Biomark; 2016; 16(2):265-73. PubMed ID: 26756617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment monitoring of colorectal cancer by integrated analysis of plasma concentration and sequencing of circulating tumor DNA.
    Yeh YM; Lin PC; Lee CT; Chen SH; Lin BW; Lin SC; Chen PC; Chan RH; Shen MR
    Mol Cancer; 2020 Oct; 19(1):150. PubMed ID: 33106181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma.
    Komatsu S; Ichikawa D; Takeshita H; Tsujiura M; Morimura R; Nagata H; Kosuga T; Iitaka D; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Otsuji E
    Br J Cancer; 2011 Jun; 105(1):104-11. PubMed ID: 21673684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.